Cargando…
A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1
HIV-1 infection is a complex, multi-step process involving not only viral, but also multiple cellular factors. To date, drug discovery methods have primarily focused on the inhibition of single viral proteins. We present an efficient and unbiased approach, compatible with biosafety level 1 (BSL-1) c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290285/ https://www.ncbi.nlm.nih.gov/pubmed/32466195 http://dx.doi.org/10.3390/v12050580 |
_version_ | 1783545640108687360 |
---|---|
author | Ellinger, Bernhard Pohlmann, Daniel Woens, Jannis Jäkel, Felix M. Reinshagen, Jeanette Stocking, Carol Prassolov, Vladimir S. Fehse, Boris Riecken, Kristoffer |
author_facet | Ellinger, Bernhard Pohlmann, Daniel Woens, Jannis Jäkel, Felix M. Reinshagen, Jeanette Stocking, Carol Prassolov, Vladimir S. Fehse, Boris Riecken, Kristoffer |
author_sort | Ellinger, Bernhard |
collection | PubMed |
description | HIV-1 infection is a complex, multi-step process involving not only viral, but also multiple cellular factors. To date, drug discovery methods have primarily focused on the inhibition of single viral proteins. We present an efficient and unbiased approach, compatible with biosafety level 1 (BSL-1) conditions, to identify inhibitors of HIV-1 reverse transcription, intracellular trafficking, nuclear entry and genome integration. Starting with a fluorescent assay setup, we systematically improved the screening methodology in terms of stability, efficiency and pharmacological relevance. Stability and throughput were optimized by switching to a luciferase-based readout. BSL-1 compliance was achieved without sacrificing pharmacological relevance by using lentiviral particles pseudo-typed with the mouse ecotropic envelope protein to transduce human PM1 T cells gene-modified to express the corresponding murine receptor. The cellular assay was used to screen 26,048 compounds selected for maximum diversity from a 200,640-compound in-house library. This yielded z’ values greater than 0.8 with a hit rate of 3.3% and a confirmation rate of 50%. We selected 93 hits and enriched the collection with 279 similar compounds from the in-house library to identify promising structural features. The most active compounds were validated using orthogonal assay formats. The similarity of the compound profiles across the different platforms demonstrated that the reported lentiviral assay system is a robust and versatile tool for the identification of novel HIV-1 inhibitors. |
format | Online Article Text |
id | pubmed-7290285 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72902852020-06-15 A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1 Ellinger, Bernhard Pohlmann, Daniel Woens, Jannis Jäkel, Felix M. Reinshagen, Jeanette Stocking, Carol Prassolov, Vladimir S. Fehse, Boris Riecken, Kristoffer Viruses Article HIV-1 infection is a complex, multi-step process involving not only viral, but also multiple cellular factors. To date, drug discovery methods have primarily focused on the inhibition of single viral proteins. We present an efficient and unbiased approach, compatible with biosafety level 1 (BSL-1) conditions, to identify inhibitors of HIV-1 reverse transcription, intracellular trafficking, nuclear entry and genome integration. Starting with a fluorescent assay setup, we systematically improved the screening methodology in terms of stability, efficiency and pharmacological relevance. Stability and throughput were optimized by switching to a luciferase-based readout. BSL-1 compliance was achieved without sacrificing pharmacological relevance by using lentiviral particles pseudo-typed with the mouse ecotropic envelope protein to transduce human PM1 T cells gene-modified to express the corresponding murine receptor. The cellular assay was used to screen 26,048 compounds selected for maximum diversity from a 200,640-compound in-house library. This yielded z’ values greater than 0.8 with a hit rate of 3.3% and a confirmation rate of 50%. We selected 93 hits and enriched the collection with 279 similar compounds from the in-house library to identify promising structural features. The most active compounds were validated using orthogonal assay formats. The similarity of the compound profiles across the different platforms demonstrated that the reported lentiviral assay system is a robust and versatile tool for the identification of novel HIV-1 inhibitors. MDPI 2020-05-25 /pmc/articles/PMC7290285/ /pubmed/32466195 http://dx.doi.org/10.3390/v12050580 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ellinger, Bernhard Pohlmann, Daniel Woens, Jannis Jäkel, Felix M. Reinshagen, Jeanette Stocking, Carol Prassolov, Vladimir S. Fehse, Boris Riecken, Kristoffer A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1 |
title | A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1 |
title_full | A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1 |
title_fullStr | A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1 |
title_full_unstemmed | A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1 |
title_short | A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1 |
title_sort | high-throughput hiv-1 drug screening platform, based on lentiviral vectors and compatible with biosafety level-1 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290285/ https://www.ncbi.nlm.nih.gov/pubmed/32466195 http://dx.doi.org/10.3390/v12050580 |
work_keys_str_mv | AT ellingerbernhard ahighthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT pohlmanndaniel ahighthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT woensjannis ahighthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT jakelfelixm ahighthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT reinshagenjeanette ahighthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT stockingcarol ahighthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT prassolovvladimirs ahighthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT fehseboris ahighthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT rieckenkristoffer ahighthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT ellingerbernhard highthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT pohlmanndaniel highthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT woensjannis highthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT jakelfelixm highthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT reinshagenjeanette highthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT stockingcarol highthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT prassolovvladimirs highthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT fehseboris highthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 AT rieckenkristoffer highthroughputhiv1drugscreeningplatformbasedonlentiviralvectorsandcompatiblewithbiosafetylevel1 |